IDXXHealthcare · Diagnostics & ResearchThe 14 Wall Street analysts covering IDEXX Laboratories, Inc. hold a median 12-month price target of $708 — +22.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 95 of 100 as at 28 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores IDEXX Laboratories, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (99): The business earns solid, repeatable profits on what it owns.
Accruals (56): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (6): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on IDXX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +22.8% from it.
Of the 20 most recent actions, 2 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Oct 2026 | UBS | Maintains | Neutral | $670 → $627 |
| 16 Oct 2026 | JP Morgan | Maintains | Overweight | $775 → $750 |
| 12 Oct 2026 | Keybanc | Initiates | Sector Weight | — |
| 11 Aug 2026 | Barclays | Maintains | Overweight | — |
| 11 Aug 2026 | Barclays | Maintains | Overweight | $800 → $710 |
| 5 Aug 2026 | Citigroup | Maintains | Neutral | — |
| 5 Aug 2026 | Citigroup | Maintains | Neutral | $650 → $670 |
| 5 Aug 2026 | UBS | Maintains | Neutral | — |
| 5 Aug 2026 | UBS | Maintains | Neutral | $620 → $670 |
| 27 July 2026 | UBS | Maintains | Neutral | — |
| 27 July 2026 | UBS | Maintains | Neutral | $640 → $620 |
| 28 Apr 2026 | UBS | Maintains | Neutral | $730 → $640 |
| 28 Apr 2026 | UBS | Maintains | Neutral | — |
| 15 Apr 2026 | Citigroup | Initiates | Neutral | — |
| 31 Mar 2026 | Stifel | Maintains | Buy | — |
| 9 Feb 2026 | Piper Sandler | Maintains | Neutral | — |
| 5 Feb 2026 | Barclays | Maintains | Overweight | — |
| 3 Feb 2026 | BTIG | Maintains | Buy | — |
| 3 Feb 2026 | UBS | Maintains | Neutral | — |
| 9 Dec 2025 | Barclays | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
IDXX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, IDEXX Laboratories, Inc. returned −8.2% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 19% of US stocks
Cheaper than 14% of US stocks
Cheaper than 3% of US stocks
Cheaper than 9% of US stocks
Higher than 53% of US stocks
Higher than 54% of US stocks
Higher than 77% of US stocks
Higher than 89% of US stocks
Higher than 86% of US stocks
Higher than 95% of US stocks
Higher than 99% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
IDEXX Laboratories, Inc. has a market value of $44.2B and an enterprise value of $45.1B.
Revenue in the twelve months to 30 June 2026: $4.6B. The latest quarter grew 9.7% year on year.
Net income over the same four quarters: $1.1B, a 25.0% net margin.
Diluted earnings per share, trailing twelve months: $14.22.
Free cash flow in the twelve months to 30 June 2026: $1.2B.
IDEXX Laboratories, Inc. spent $1.2B on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 38.8×; forward P/E: 33.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
IDEXX Laboratories, Inc. employs 11,000 people — $414K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own IDEXX Laboratories, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research previews Idexx’s quarter ended September 2026, focusing on estimates for key metrics beyond Wall Street’s revenue and earnings estimates.
Why it matters — IDXX watchers can review the additional consensus estimates ahead of the company’s Q3 earnings.
Zacks Investment Research says Wall Street expects earnings growth when Idexx Laboratories reports next week. The excerpt says the company has two key ingredients for a likely earnings beat but provides no further details.
Why it matters — IDXX watchers may note the expectations for the upcoming earnings report and the stated possibility of an earnings beat.
IDEXX Laboratories heads into Q3 earnings with expected revenue and EPS growth, supported by CAG Diagnostics momentum, higher testing volumes and software gains.
Why it matters — IDXX watchers may track these cited business trends as the company approaches its Q3 earnings report.
Zacks Investment Research says Idexx has a history of earnings surprises and currently has two key ingredients it views as supporting a likely beat in its next quarterly report.
Why it matters — IDXX watchers may note the report’s positive assessment of the company’s prospects for beating estimates in its upcoming earnings release.
Zacks Investment Research says its Zacks Earnings ESP can help identify stocks expected to beat quarterly earnings estimates. The headline refers to two medical stocks, but the excerpt does not identify them or provide details about their earnings expectations.
Why it matters — The excerpt does not establish whether IDEXX is one of the stocks discussed or provide IDEXX-specific earnings information.
The 14 Wall Street analysts covering IDEXX Laboratories, Inc. have a median 12-month price target of $708, with estimates ranging from $470 to $805. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering IDEXX Laboratories, Inc., 9 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks IDEXX Laboratories, Inc. 95 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, IDEXX Laboratories, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +22.8% from the last close, and Ticker Nerd's factor model ranks IDEXX Laboratories, Inc. 95 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering IDEXX Laboratories, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IDXX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $470 to $805 over the next 12 months.
IDEXX Laboratories, Inc. returned -8.2% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
IDEXX Laboratories, Inc. is a global diagnostics and software company focused on animal health, water quality, and agricultural testing.
The most recent item we track (Zacks Investment Research, 28 Oct 2026): "Gear Up for Idexx (IDXX) Q3 Earnings: Wall Street Estimates for Key Metrics". Zacks Investment Research previews Idexx’s quarter ended September 2026, focusing on estimates for key metrics beyond Wall Street’s revenue and earnings estimates.
IDEXX Laboratories, Inc. is a global diagnostics and software company focused on animal health, water quality, and agricultural testing. IDEXX Laboratories, Inc. develops and supplies in-clinic veterinary diagnostic instruments, consumable test kits, reference laboratory services, and practice management software that help veterinarians diagnose and monitor companion animals. The company also provides testing solutions for livestock, poultry, and dairy producers, along with water microbiology products used to assess drinking water safety and quality. Its product portfolio is built around recurring consumables, laboratory workflows, and integrated software tools that support everyday clinical and operational decisions. IDEXX Laboratories, Inc. serves veterinary practices, animal health professionals, utilities, and food-production customers across global markets, making it an important provider of diagnostic infrastructure in the broader healthcare and environmental testing ecosystem.
CEO Mr. Michael G. Erickson Ph.D. · 11,000 employees · United States · https://www.idexx.com
